Blue Jet Healthcare LimitedQ1 FY27 Results & Financial Update
Blue Jet Healthcare Limited: Q1 FY27 standalone results and company financials – revenue ₹293.11 Cr, PAT ₹78.26 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Blue Jet Healthcare price & chart
Market price₹528.50
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Blue Jet Healthcare Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
For the first quarter ended June 30, 2026 (Q1 FY27), Blue Jet Healthcare reported revenue from operations of INR 293.113 crore alongside other income of INR 15.237 crore, bringing total income to INR 308.350 crore.
The company registered a profit before tax (PBT) of INR 105.946 crore for the quarter, after accounting for total expenses of INR 202.404 crore.
Net profit after tax (PAT) for Q1 FY27 stood at INR 78.264 crore, reflecting a PAT margin of approximately 26.70% on operating revenue.
Basic and diluted earnings per share (EPS) for the interim period were reported at INR 4.51 each, noting that interim earnings are not annualised.
Cost of materials consumed represented a major expense component at INR 178.878 crore, offset by a positive inventory movement of INR 41.767 crore relating to finished goods and work-in-progress.
Employee benefits expense was recorded at INR 20.117 crore, while finance costs remained modest at INR 0.660 crore and depreciation and amortisation stood at INR 6.706 crore.
Tax expense for the quarter totalled INR 27.682 crore, comprising a current tax provision of INR 26.500 crore and deferred tax of INR 1.182 crore.
01 · Business model
What does Blue Jet Healthcare do?
Blue Jet Healthcare Limited operates as a specialty pharmaceutical and chemical manufacturer, focusing on niche segments including artificial sweeteners, contrast media intermediates, pharma intermediates, and active pharmaceutical ingredients (APIs).
The company's operations are structured to serve global and domestic pharmaceutical and healthcare enterprises, leveraging advanced manufacturing infrastructure spread across multiple units in Maharashtra, India.
Blue Jet Healthcare operates entirely on a standalone basis with no subsidiaries, associates, or joint ventures as of June 30, 2026.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹293.11 Cr |
| Total income | ₹308.35 Cr |
| Profit before tax | ₹105.95 Cr |
| Profit after tax | ₹78.26 Cr |
| EPS | ₹4.51 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 26.7% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 36.1% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹15.24 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Generated INR 293.113 crore from operations during Q1 FY27 across the company's core product lines including artificial sweeteners and contrast media intermediates.
Contributed INR 15.237 crore in other income, lifting total income for the quarter to INR 308.350 crore.
What drove margins
Maintained low finance costs of INR 0.660 crore alongside depreciation and amortisation of INR 6.706 crore, supporting a robust quarterly PAT margin of 26.70%.
04 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company is engaged in the manufacturing of Artificial Sweeteners, Contrast Media Intermediates, Pharma Intermediates, and APIs used in pharmaceutical and healthcare products, constituting a single reportable business segment under IND AS 108.
05 · Strategy & new businesses
How the company is trying to change its growth mix
The company does not have any subsidiaries, associates, or joint ventures as on June 30, 2026, meaning consolidated financial statements are not applicable.
06 · Beyond the numbers
What changed beyond the numbers
Reported update
Board Approvals and Leadership Re-appointments
The Board of Directors approved the re-appointment of Mr. Akshay B. Arora as Whole Time Director and Executive Chairman, and Mr. Shiven Akshay Arora as Managing Director, both for a further five-year term effective from April 13, 2027, subject to shareholder approval.
Reported update
Statutory Auditor Re-appointment
The Board approved the re-appointment of M/s KKC & Associates LLP as Statutory Auditors for a second consecutive five-year term until the conclusion of the 63rd AGM.
Reported update
Post-Quarter QIP Allotment
Subsequent to the quarter ended June 30, 2026, the company allotted 1,58,10,276 equity shares of face value INR 2 each to eligible Qualified Institutional Buyers at INR 506 per share, aggregating to INR 800.00 crore.
07 · Key Q&A
The quarter, answered directly
What does Blue Jet Healthcare do?
Blue Jet Healthcare Limited operates as a specialty pharmaceutical and chemical manufacturer, focusing on niche segments including artificial sweeteners, contrast media intermediates, pharma intermediates, and active pharmaceutical ingredients (APIs).
What is the clearest takeaway from Q1 FY27?
For the first quarter ended June 30, 2026 (Q1 FY27), Blue Jet Healthcare reported revenue from operations of INR 293.113 crore alongside other income of INR 15.237 crore, bringing total income to INR 308.350 crore.
What drove revenue or demand?
Generated INR 293.113 crore from operations during Q1 FY27 across the company's core product lines including artificial sweeteners and contrast media intermediates.
What mattered most for margins or profitability?
Maintained low finance costs of INR 0.660 crore alongside depreciation and amortisation of INR 6.706 crore, supporting a robust quarterly PAT margin of 26.70%.
What changed operationally beyond the headline numbers?
The company does not have any subsidiaries, associates, or joint ventures as on June 30, 2026, meaning consolidated financial statements are not applicable.
What should the next disclosure help confirm?
The 58th Annual General Meeting of the company is scheduled to be held on September 21, 2026, via Video Conferencing or Other Audio-Visual Means.
08 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
09 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Upcoming Annual General Meeting: The 58th Annual General Meeting of the company is scheduled to be held on September 21, 2026, via Video Conferencing or Other Audio-Visual Means.
- 02
Dividend Record Date: September 14, 2026, has been set as the record date for determining entitlement to receive a dividend of INR 1.20 per equity share (60%) for the financial year 2025-26.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.